TAK-861

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

1 competitor in Hypersomnia

#DrugCompanyPhaseTrials

1

Nuvigil

NNuvo Research GmbH

Approved

—2

TAK-861

Takeda

Phase 3

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Narcolepsy2 trials

A Study of TAK-861 in Participants With Narcolepsy Type 1

Completed·Takeda·Phase 2·NCT05687903·112 enrolled

A Study of TAK-861 in Participants With Narcolepsy Type 2

Completed·Takeda·Phase 2·NCT05687916·71 enrolled

Narcolepsy Type 12 trials

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Completed·Takeda·Phase 3·NCT06470828·168 enrolled

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Completed·Takeda·Phase 3·NCT06505031·105 enrolled

Hypersomnia1 trial

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Recruiting·Takeda·Phase 2/3·NCT05816382·500 enrolled

Narcolepsy Type 1 (NT1)1 trial

A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Active, not recruiting·Takeda·Phase 3·NCT07363720·98 enrolled

Details

Drug Info

Related News